16,113 Shares in Illumina, Inc. $ILMN Bought by Leeward Financial Partners LLC

Leeward Financial Partners LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 16,113 shares of the life sciences company’s stock, valued at approximately $4,410,000. Illumina accounts for about 1.2% of Leeward Financial Partners LLC’s portfolio, making the stock its 29th biggest holding.

Several other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. bought a new position in shares of Illumina in the second quarter worth $3,374,423,000. Plato Investment Management Ltd bought a new stake in shares of Illumina during the 2nd quarter valued at $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Illumina during the 2nd quarter valued at $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina during the 2nd quarter valued at $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Illumina during the 2nd quarter worth about $6,711,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity

In other news, Director Keith Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the sale, the director owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,061,850 shares of company stock worth $436,479,102. Insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ILMN shares. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research note on Wednesday, August 5th. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Stifel Nicolaus increased their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Argus increased their price target on shares of Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, September 3rd. Ten investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average target price of $234.41.

Illumina Stock Performance

Shares of ILMN stock opened at $269.42 on Monday. The company has a market capitalization of $40.68 billion, a PE ratio of 50.26, a price-to-earnings-growth ratio of 3.82 and a beta of 1.41. Illumina, Inc. has a 52-week low of $94.00 and a 52-week high of $309.35. The business’s fifty day moving average is $242.35 and its 200 day moving average is $191.54. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the previous year, the business earned $1.19 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s upcoming quarterly report could benefit from strong clinical demand, NovaSeq X adoption, new instrument placements, and consumables growth. Analysts also expect year-over-year earnings growth and see potential for an earnings beat, although research-market weakness remains a concern. ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
• Positive Sentiment: The company launched three early-access capabilities for its BioInsight Platform—Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts. The tools expand Illumina’s AI-driven variant prioritization, sequencing analysis, and genomic-data workflow offerings, potentially increasing the strategic importance of software and data services. How Investors May Respond To Illumina BioInsight AI Rollout
• Neutral Sentiment: Illumina is expected to report quarterly results next week. The event is a major near-term catalyst, with investor attention likely centered on clinical demand, NovaSeq X placements, consumables revenue, and management’s outlook. Illumina Expected to Release Quarterly Earnings on Thursday
• Neutral Sentiment: The consensus price target was raised 19.65% to $250.77, signaling improved analyst expectations, but that target remains below Illumina’s recent trading level and may limit upside if not revised further. Illumina Consensus Price Target Increased
• Negative Sentiment: Stephens downgraded Illumina to Equal Weight, reducing a potential source of buying pressure and reflecting a more cautious view of the stock’s risk-reward profile. Stephens Downgrades Illumina to Equal Weight
• Negative Sentiment: Illumina recently fell alongside Twist Bioscience and other AI- and genomics-related stocks in a broad technology selloff, indicating that sector sentiment—not company-specific news—has also been driving volatility. Twist Bioscience and Illumina Slide as AI and Genomics Stocks Sell Off

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.